References
- American Cancer SocietyCancer Facts and Figures 2003Atlanta, GAAmerican Cancer Society2003
- MinceyBAPerezEAConcise review for clinicians: advances in screening, diagnosis and treatment of breast cancerMayo Clin Proc20047981081615182098
- CarlsonRWAndersonBOBensingerWNCCN Practice Guidelines in Oncology, Version 2National Comprehensive Cancer Network2002
- GoRSAdjeiAAReview of the comparative pharmacology and clinical activity of cisplatin and carboplatinJ Clin Oncol19991740942210458260
- FountzilasGAthanassiadesAPapadimitriouVPaclitaxel and carboplatin as first-line chemotherapy for advanced breast cancerOncology (Huntingt)199812Suppl 145489516604
- PerezEAVogelCLIrwinDHMulticenter Phase II trial of weekly paclitaxel in women with metastatic breast cancerJ Clin Oncol2001194216422311709565
- SeidmanADBerryDCirrincioneCPhase III weekly paclitaxel via 1-hr infusion vs. standard 3-hr infusion every third week in the treatment of metastatic breast cancer, with trastuzumab for HER2+ MBC and randomized to trastuzumab for HER2 normal MBCProc Am Soc Clin Oncol2004236sa
- MillerKDE2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancerClin Breast Cancer20033642142212636887
- RobertNJDiérasVGlaspyJRIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancerJ Clin Oncol201129101252126021383283
- PivotXSchneeweissAVermaSEfficacy and safety of bevacizumab in combination with docetaxel for the first line treatment with elderly patients with locally recurrent or metastatic breast cancer: results from AVADOEur J Cancer2011472387239521757334
- MilesDWChanADirixLYPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first line treatment of human epidermal growth factor receptor 2 negative metastatic breast cancerJ Clin Oncol201028203239324720498403
- OcanaAAmirEVeraFAddition of bevacizumab to chemotherapy for treatment of solid tumor; similar results but different conclusionsJ Clin Oncol201129325425621149670
- FitchRASumanVJMailliardJAN9932: Phase II cooperative group trial of docetaxel (D) and carboplatin (CBDCA) as first-line chemotherapy for metastatic breast cancer (MBA)Proc Am Soc Clin Oncol20032223
- PerezEAHillmanDWStellaPJA Phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinomaCancer20008812413110618614
- LoeschDRobertNAsmarLPhase II multicenter trial of a weekly paclitaxel and carboplatin regimen in patients with advanced breast cancerJ Clin Oncol2002203857386412228205
- BrufskyAMatinKClearyDA Phase II study of carboplatin and docetaxel as first line chemotherapy for metastatic breast cancerProc Am Soc Clin Oncol20022152b
- MartinMDiaz-RubioECasadoACarboplatin: an active drug in metastatic breast cancerJ Clin Oncol1992104334371740682
- O’BrienMETalbotDCSmithIECarboplatin in the treatment of advanced breast cancer: a Phase II study using a pharmacokinetically guided dose scheduleJ Clin Oncol199311211221178229125